Herbs (Global Traditional) · Traditional Chinese Medicine
Chinese Skullcap (Scutellaria baicalensis) (Scutellaria baicalensis)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Chinese skullcap (Scutellaria baicalensis) contains bioactive flavonoids baicalin, baicalein, and wogonin that modulate inflammatory pathways. These compounds inhibit nuclear factor-κB (NF-κB) and reduce production of inflammatory mediators like IL-5 and IgE.
Chinese Skullcap (Scutellaria baicalensis), also known as Baikal skullcap, is a flowering plant in the Lamiaceae family native to China, Japan, and Korea, primarily sourced from its roots. The plant is extracted using aqueous or ethanol extraction methods of dried root slices, yielding flavonoid-rich concentrates containing over 40-60 identified structures including glucuronides and aglycones.
Current evidence for Chinese Skullcap is primarily preclinical, consisting of in vitro and animal model studies for anti-inflammatory, anti-allergic, hepatoprotective, and anticancer effects. Human clinical trials with specific PMIDs were not detailed in available research, with only one bioavailability study using 5.2g root powder in 10 subjects noted.
Preclinical studies used oral skullcap extract at 25 mg/kg body weight in mice. Human bioavailability study used 5.2g root powder with 200ml water. Standardized extracts typically contain baicalin (40.6%), wogonoside (15.5%), and other flavonoids totaling 68.5%. Consult a healthcare provider before starting any new supplement.
Chinese Skullcap (Scutellaria baicalensis) root is not consumed as a food source and thus lacks significant macronutrient relevance in typical dosing contexts (standardized extracts: 400–1500 mg/day; dried root decoctions: 3–9 g/day in TCM practice). Its nutritional significance lies almost entirely in its bioactive phytochemical composition. Primary flavonoids include: baicalin (baicalein-7-O-glucuronide) at approximately 10–35% dry weight of the root, making it the dominant compound; baicalein (aglycone form of baicalin) at 1–5% dry weight; wogonin at 1–4% dry weight; wogonoside (wogonin-7-O-glucuronide) at 1–3% dry weight; and oroxylin A at 0.5–2% dry weight. Minor flavonoids include scutellarein, neobaicalein, and chrysin derivatives present at <1% each. Non-flavonoid constituents include iridoids (e.g., catalpol), phenylethanoids, and essential oils in trace amounts (<0.1%). Mineral content of the dried root includes modest calcium (~200–400 mg/100g dry weight), potassium (~500–800 mg/100g dry weight), and magnesium (~100–200 mg/100g dry weight), though these are nutritionally irrelevant at supplemental doses. Crude fiber content is approximately 15–25% of dry root weight. Protein content is approximately 8–12% dry weight but is not bioavailable in meaningful quantities at standard dosing. Bioavailability notes: Baicalin undergoes extensive intestinal and hepatic hydrolysis to baicalein by gut microbial β-glucuronidase; baicalein exhibits higher membrane permeability (Papp ~10–20 × 10⁻⁶ cm/s in Caco-2 models) than baicalin (Papp ~2–5 × 10⁻⁶ cm/s). Oral bioavailability of baicalin is estimated at 2–10% due to first-pass metabolism and poor aqueous solubility; lipid-based or phospholipid complex formulations improve absorption by approximately 2–3 fold. Wogonin bioavailability is similarly low (~10–15% in rodent models). Peak plasma concentrations of baicalein following 400 mg baicalin-equivalent dose are reported at approximately 0.5–2 µg/mL in human pharmacokinetic studies. Co-administration with food or lipids modestly enhances absorption of lipophilic aglycones.
The primary bioactive compounds baicalin, baicalein, and wogonin inhibit nuclear factor-κB (NF-κB) signaling, reducing inflammatory cytokine production. These flavonoids suppress Th2 immune responses by decreasing IL-4, IL-5, and IL-13 expression. The compounds also modulate liver enzyme activity and provide hepatoprotective effects through antioxidant pathways.
Current evidence comes primarily from animal studies and preliminary research. Asthma models show reduced IgE and IL-5 levels with Chinese skullcap extract administration. Preclinical liver studies demonstrate decreased AST and ALT enzymes, indicating potential hepatoprotective effects. Human clinical trials are limited, making the evidence preliminary and requiring further validation in controlled studies.
Chinese skullcap is generally well-tolerated but may cause drowsiness or gastrointestinal upset in some individuals. It may interact with anticoagulant medications due to potential bleeding risk enhancement. The herb should be used cautiously with sedative medications as it may amplify drowsiness effects. Pregnant and nursing women should avoid use due to insufficient safety data.
